Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
AMIA Annu Symp Proc ; 2022: 1227-1236, 2022.
Article in English | MEDLINE | ID: mdl-37128413

ABSTRACT

Remdesivir has been widely used for the treatment of Coronavirus (COVID) in hospitalized patients, but its nephrotoxicity is still under investigation1. Given the paucity of knowledge regarding the mechanism and optimal treatment of the development of acute kidney injury (AKI) in the setting of COVID, we analyzed the role of remdesivir and built multifactorial causal models of COVID-AKI by applying causal discovery machine learning techniques. Risk factors of COVID-AKI and renal function measures were represented in a temporal sequence using longitudinal data from EHR. Our models successfully recreated known causal pathways to changes in renal function and interactions with each other and examined the consistency of high-level causal relationships over a 4-day course of remdesivir. Results indicated a need for assessment of renal function on day 2 and 3 use of remdesivir, while uncovering that remdesivir may pose less risk to AKI than existing conditions of chronic kidney disease.


Subject(s)
Acute Kidney Injury , COVID-19 , Drug-Related Side Effects and Adverse Reactions , Humans , SARS-CoV-2 , COVID-19 Drug Treatment , Acute Kidney Injury/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...